These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 31532560)

  • 1. Editorial: the reduction of faecal calprotectin during exclusive enteral nutrition is lost rapidly after food reintroduction.
    Wall CL; Day AS
    Aliment Pharmacol Ther; 2019 Oct; 50(7):824-825. PubMed ID: 31532560
    [No Abstract]   [Full Text] [Related]  

  • 2. The reduction of faecal calprotectin during exclusive enteral nutrition is lost rapidly after food re-introduction.
    Logan M; Clark CM; Ijaz UZ; Gervais L; Duncan H; Garrick V; Curtis L; Buchanan E; Cardigan T; Armstrong L; Delahunty C; Flynn DM; Barclay AR; Tayler R; McDonald E; Milling S; Hansen RK; Gerasimidis K; Russell RK
    Aliment Pharmacol Ther; 2019 Sep; 50(6):664-674. PubMed ID: 31342536
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Letter: reproducible evidence shows that exclusive enteral nutrition significantly reduces faecal calprotectin concentrations in children with active Crohn's disease.
    Logan M; Ijaz UZ; Hansen R; Gerasimidis K; Russell RK
    Aliment Pharmacol Ther; 2017 Dec; 46(11-12):1119-1120. PubMed ID: 29105140
    [No Abstract]   [Full Text] [Related]  

  • 4. Letter: reproducible evidence shows that exclusive enteral nutrition significantly reduces faecal calprotectin concentrations in children with active Crohn's disease-Authors' reply.
    Feathers A; Swaminath A; Ananthakrishnan AN; Falzon L; Li Ferry S
    Aliment Pharmacol Ther; 2017 Dec; 46(11-12):1121. PubMed ID: 29105134
    [No Abstract]   [Full Text] [Related]  

  • 5. Dietary triggers of gut inflammation following exclusive enteral nutrition in children with Crohn's disease: a pilot study.
    Gkikas K; Logan M; Nichols B; Ijaz UZ; Clark CM; Svolos V; Gervais L; Duncan H; Garrick V; Curtis L; Buchanan E; Cardigan T; Armstrong L; Delahunty C; Flynn DM; Barclay AR; Tayler R; Milling S; Hansen R; Russell RK; Gerasimidis K
    BMC Gastroenterol; 2021 Dec; 21(1):454. PubMed ID: 34861829
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serial fecal calprotectin changes in children with Crohn's disease on treatment with exclusive enteral nutrition: associations with disease activity, treatment response, and prediction of a clinical relapse.
    Gerasimidis K; Nikolaou CK; Edwards CA; McGrogan P
    J Clin Gastroenterol; 2011 Mar; 45(3):234-9. PubMed ID: 20871409
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systematic review with meta-analysis: enteral nutrition therapy for the induction of remission in paediatric Crohn's disease.
    Swaminath A; Feathers A; Ananthakrishnan AN; Falzon L; Li Ferry S
    Aliment Pharmacol Ther; 2017 Oct; 46(7):645-656. PubMed ID: 28815649
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fecal calprotectin is not a clinically useful marker for the prediction of the early nonresponse to exclusive enteral nutrition in pediatric patients with Crohn disease.
    Copova I; Hradsky O; Zarubova K; Gonsorcikova L; Potuznikova K; Lerchova T; Nevoral J; Bronsky J
    Eur J Pediatr; 2018 Nov; 177(11):1685-1693. PubMed ID: 30128744
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Impact of Compliance During Exclusive Enteral Nutrition on Faecal Calprotectin in Children With Crohn Disease.
    Mckirdy S; Russell RK; Svolos V; Gkikas K; Logan M; Hansen R; Gerasimidis K
    J Pediatr Gastroenterol Nutr; 2022 Jun; 74(6):801-804. PubMed ID: 35192573
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diet to the Rescue: Cessation of Pharmacotherapy After Initiation of Exclusive Enteral Nutrition (EEN) Followed by Strict and Liberalized Specific Carbohydrate Diet (SCD) in Crohn's Disease.
    Nakayuenyongsuk W; Christofferson M; Nguyen K; Burgis J; Park KT
    Dig Dis Sci; 2017 Oct; 62(10):2686-2689. PubMed ID: 28084605
    [No Abstract]   [Full Text] [Related]  

  • 11. Faecal calprotectin - the Crohn's disease activity predictor of the future.
    Ramphul P
    Clin Med (Lond); 2016 Jun; 16 Suppl 3(Suppl 3):s28. PubMed ID: 27252331
    [No Abstract]   [Full Text] [Related]  

  • 12. Chronic cheilitis: Faecal calprotectin test a way to diagnose oral Crohn's disease.
    Harris V; Smith SD
    Australas J Dermatol; 2017 Nov; 58(4):324-325. PubMed ID: 28731524
    [No Abstract]   [Full Text] [Related]  

  • 13. The utility of faecal calprotectin to predict post-operative recurrence in Crohńs disease.
    Herranz Bachiller MT; Barrio Andres J; Fernandez Salazar L; Ruiz-Zorrilla R; Sancho Del Val L; Atienza Sanchez R
    Scand J Gastroenterol; 2016; 51(6):720-6. PubMed ID: 26758472
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prediction of Crohn's disease relapse with faecal calprotectin in infliximab responders: a prospective study.
    Deshpande AR; Strobel S
    Aliment Pharmacol Ther; 2011 Sep; 34(5):586. PubMed ID: 21806647
    [No Abstract]   [Full Text] [Related]  

  • 15. What is the faecal calprotectin test?
    Drug Ther Bull; 2014 Sep; 52(9):102-4. PubMed ID: 25213590
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation between faecal calprotectin and magnetic resonance imaging (MRI) in the evaluation of inflammatory pattern in Crohn's disease.
    Zippi M; Al Ansari N; Siliquini F; Severi C; Kagarmanova A; Maffia C; Parlanti S; Garbarino V; Maccioni F
    Clin Ter; 2010; 161(2):e53-6. PubMed ID: 20499020
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn's disease and histological findings.
    Sipponen T; Kärkkäinen P; Savilahti E; Kolho KL; Nuutinen H; Turunen U; Färkkilä M
    Aliment Pharmacol Ther; 2008 Nov; 28(10):1221-9. PubMed ID: 18752630
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prediction of Crohn's disease relapse with faecal calprotectin in infliximab responders: a prospective study.
    Laharie D; Mesli S; El Hajbi F; Chabrun E; Chanteloup E; Capdepont M; Razaire S; de Lédinghen V; Zerbib F
    Aliment Pharmacol Ther; 2011 Aug; 34(4):462-9. PubMed ID: 21671970
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Faecal calprotectin assay after induction with anti-Tumour Necrosis Factor α agents in inflammatory bowel disease: Prediction of clinical response and mucosal healing at one year.
    Guidi L; Marzo M; Andrisani G; Felice C; Pugliese D; Mocci G; Nardone O; De Vitis I; Papa A; Rapaccini G; Forni F; Armuzzi A
    Dig Liver Dis; 2014 Nov; 46(11):974-9. PubMed ID: 25096964
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Faecal calprotectin but not C-reactive protein (CRP) or Crohn's Disease Activity Index (CDAI) may predict post-operative endoscopic recurrence of Crohn's disease.
    Papamichael K; Karatzas P; Mantzaris GJ
    J Crohns Colitis; 2013 Dec; 7(12):e700-1. PubMed ID: 23953238
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.